By the Chief Dermatology Consultant, Dubai Aesthetic Medicine Centre Published on the OYAY LAB Professional Blog
Preface
In over a decade of clinical practice at the intersection of medical dermatology and advanced aesthetic medicine here in Dubai — a market that demands both cutting-edge innovation and uncompromising client safety — I have evaluated hundreds of energy-based devices. It is rare that a technology genuinely reframes our clinical thinking. Cold plasma is one such technology.
This article is written specifically for licensed aesthetic professionals, clinic directors, and paramedical practitioners who are considering integrating cold plasma into their wound healing and post-procedural recovery protocols. I will analyse, from a rigorous technical standpoint, why OYAY LAB's Cold Plasma System occupies a fundamentally safer physiological space for wound healing compared to traditional thermal energy devices — including non-ablative fractional lasers and other light-based technologies commonly used in our industry.
This is not a marketing document. This is a clinical analysis grounded in biophysics, published dermatological science, and direct technical comparison.
Section 1: The Complexity of Wound Healing — Why "Safe Enough" Is Never Sufficient
Before evaluating any technology, we must first respect the biological complexity of the wound healing cascade. Wound healing is not a single event — it is a precisely orchestrated, four-phase biological process:
- Haemostasis – Fibrin clot formation and vasoconstriction within minutes of injury.
- Inflammation – Neutrophils and macrophages migrate to the wound site, clearing debris and initiating repair signals.
- Proliferation – Fibroblast activation, granulation tissue formation, re-epithelialisation, and collagen deposition.
- Remodelling – Type III collagen is gradually replaced by stronger Type I collagen, restoring tensile strength.
Any energy-based intervention introduced during or after wound healing must not disrupt this cascade. It must work with the body's regenerative biology, not against it.
Herein lies the fundamental challenge with traditional thermal devices.
Section 2: The Inherent Safety Limitations of Thermal and Light-Based Technologies
For context, let us briefly examine the mechanism of action of common devices used in aesthetic wound care and post-procedural recovery:
Non-Ablative Fractional Lasers (1450nm, 940nm, 1927nm) — Such as the Iris ice Plus (1450nm, 3–12 mJ/Pulse), the RelaxLight (940nm, 6–12 mJ/Pulse), and the Dora (1927nm, 2–7 mJ/Pulse) — work by delivering focused photonic energy into the dermal layers. They create microscopic thermal columns (micro-coagulation zones) that stimulate collagen remodelling through a controlled thermal injury response. Even devices classified as "non-ablative" and bearing IEC 60825 Class 1 safety ratings operate through a fundamentally thermal mechanism: the skin heals because it has been thermally insulted.
The clinical implications of this are significant when applied to wound healing contexts:
-
Heat delivery is inherently non-selective. Even with sophisticated 360° icy crystal cooling systems (as employed in devices like the Iris ice Plus), the energy pathway from epidermis to dermis involves a temperature gradient. In compromised skin — post-procedural, inflamed, or infected — thermal accumulation can exacerbate oedema and inflammatory cytokine release.
-
Laser wavelengths target chromophores. Water molecules (1450nm, 1927nm) or haemoglobin are targeted by design. In post-wound tissue with irregular vascularity and oedematous dermis, the chromophore distribution is unpredictable, increasing the risk of uneven energy absorption and localised thermal injury.
-
Recovery is mandatory. Even with NAFL (Non-Ablative Fractional Laser) technology and no formal "downtime," thermal microcoagulation requires a recovery period during which the treated tissue is in an active inflammatory state. Applying this to a wound — where inflammatory dysregulation can lead to chronic wound development — introduces unnecessary biological risk.
-
Antimicrobial efficacy is indirect. Light-based devices do not directly sterilise the wound environment. The 415nm blue light employed in devices like the Nova acne device has superficial bactericidal properties, but deep-penetrating wound pathogens (including biofilm-forming Staphylococcus aureus) are not adequately addressed by light energy alone.
These are not criticisms of these technologies in their appropriate clinical applications — fractional laser resurfacing, skin lightening, and anti-aging protocols. They are observations about the mechanistic mismatch between thermal energy delivery and the biological requirements of safe wound healing.
Section 3: Cold Plasma Physics — A Fundamentally Different Biological Mechanism
OYAY LAB's Cold Plasma System operates on a principle that is categorically different from all thermal devices.
The system uses a precisely controlled electric field to generate a low-temperature, reactive gas plume — a state of matter known as the fourth state. This plume is composed of a complex mixture of biologically active species collectively referred to as Reactive Oxygen and Nitrogen Species (RONS).
RONS include:
- Reactive Oxygen Species (ROS): Ozone (O₃), hydrogen peroxide (H₂O₂), hydroxyl radicals (·OH), superoxide (O₂⁻·), singlet oxygen (¹O₂)
- Reactive Nitrogen Species (RNS): Nitric oxide (NO), nitrogen dioxide (NO₂), dinitrogen trioxide (N₂O₃), peroxynitrite (ONOO⁻)
At first glance, "reactive species" may sound concerning. The scientific reality is far more nuanced. At the controlled, sub-cytotoxic concentrations generated by a calibrated cold plasma device, RONS function as endogenous signalling molecules — they are precisely the species your body uses to orchestrate its own healing.
The key technical distinction is temperature. Unlike thermal plasma (which operates at 4,000–5,000K), cold plasma operates at 30°C–50°C at the tissue interface. This is within the physiological range. There is no thermal injury. There is no coagulation necrosis. There is no melanin disruption.
The OYAY LAB Cold Plasma System's architecture reflects this understanding. With a peak voltage of 20KV driving a precisely modulated electric field, and three distinct handpiece configurations — Scan (0.2mm spot, 1–50 Hz), Smooth (15mm spot, 1–50 Hz), and SSR (20mm spot, 35–60 Hz) — the system provides granular control over energy density (1–50 levels) to ensure RONS delivery is calibrated precisely to the clinical indication, from targeted wound intervention (Scan) to broad-field tissue conditioning (SSR/Smooth).
Section 4: Four Mechanisms That Make Cold Plasma Specifically Safer for Wound Healing
Mechanism 1: Anti-Inflammatory Action Without Immune Suppression
Published clinical research demonstrates that Low-Temperature Cold Plasma (LTCP) significantly reduces the expression of pro-inflammatory cytokines TNF-α, IL-6, and IL-1β in wound tissue. In one peer-reviewed in vivo study, LTCP treatment reduced TNF-α and IL-1β mRNA expression levels by 55.98% and 73.91% respectively in younger subjects, and by 86.61% and 53.11% respectively in aged subjects compared to untreated controls — results that would be clinically extraordinary by any standard.
Why is this significant for wound healing safety?
Unresolved inflammation is the primary driver of chronic wound development. Prolonged elevation of TNF-α, IL-6, and IL-1β creates a pathological wound environment that prevents transition from the inflammatory to proliferative phase. Traditional thermal devices, by inducing controlled thermal injury, inherently trigger an inflammatory response to achieve their collagen-remodelling effects. When applied to compromised tissue, this can amplify rather than resolve the very inflammatory dysregulation that delays healing.
Cold plasma, by contrast, modulates inflammation through RONS signalling — downregulating pathological inflammation while preserving the acute haemostatic and bactericidal responses necessary for normal healing. It acts, in the words of the OYAY LAB technical documentation, "like a steroid without chemicals." This is biologically accurate.
Mechanism 2: Direct Antimicrobial Action — Targeting the Primary Driver of Chronic Wounds
Wound infection is the single most consequential factor in healing failure. Approximately 78.2% of chronic wounds involve biofilm-forming bacterial infection, with Staphylococcus aureus being among the most clinically significant pathogens.
OYAY LAB's Cold Plasma System addresses this through a mechanistically unique route: direct disruption of bacterial molecular structures via RONS. The electric field component of the plasma discharge breaks down bacterial cell membrane integrity, while species such as O₃ and H₂O₂ penetrate biofilm matrices that are notoriously resistant to conventional antibiotics.
Critically, this antimicrobial mechanism does not generate antibiotic resistance — a problem of profound clinical concern in contemporary wound management. Cold plasma kills bacteria through oxidative and electromagnetic stress, mechanisms to which pathogens cannot develop heritable resistance in the same manner as pharmacological agents.
Furthermore, and this is a point that is not widely discussed in aesthetic practice: recent high-quality research using 16S rRNA microbiome sequencing has demonstrated that LTCP treatment selectively reduces pathogenic bacteria (including Delftia, Stenotrophomonas, Enterococcus, and Enterobacter) while preserving and increasing beneficial microbiome species such as Muribaculaceae, Acinetobacter, and Lachnospiraceae. No laser or radiofrequency device comes close to this level of microbiological sophistication. Thermal devices, by definition, are indiscriminate — they sterilise the wound surface non-selectively, potentially disrupting the commensal microbiome that contributes to healthy tissue repair.
Mechanism 3: Active Upregulation of Tissue Repair Factors — Regeneration, Not Just Stimulus
Perhaps the most compelling dimension of cold plasma's safety profile is not what it prevents, but what it actively promotes.
Peer-reviewed research has documented that LTCP treatment significantly upregulates the following tissue repair-related growth factors:
| Growth Factor | Function in Wound Healing | LTCP Effect |
|---|---|---|
| VEGF (Vascular Endothelial Growth Factor) | Angiogenesis, new capillary formation | Upregulated by up to 91.59% |
| bFGF (Basic Fibroblast Growth Factor) | Fibroblast proliferation, ECM remodelling | Upregulated significantly |
| TGF-β (Transforming Growth Factor-β) | Collagen synthesis, wound contraction | Upregulated by up to 39.48% |
| COL-I (Type I Collagen) | Mature scar remodelling, tensile strength | Upregulated |
| α-SMA (Alpha-Smooth Muscle Actin) | Myofibroblast differentiation, wound closure | Upregulated |
This is a biologically coherent regenerative programme — the very cascade your clients' skin requires for efficient, scarless healing. OYAY LAB's system delivers this not through thermal injury (which forces a secondary healing response) but through direct RONS-mediated cell signalling, engaging fibroblasts and keratinocytes at the receptor level.
This is why the OYAY LAB technical data accurately characterises cold plasma as able to "stimulate healing like a growth factor." The characterisation is scientifically defensible.
By comparison, non-ablative lasers achieve collagen stimulation as a secondary response to controlled thermal damage. The collagen is produced to repair the laser-induced micro-injury — not to heal the original clinical wound. This mechanistic distinction is not semantic; it is clinically meaningful, particularly in post-procedural or fragile skin states.
Mechanism 4: Enhanced Cellular Proliferation and Balanced Apoptosis
Wound healing requires a precise equilibrium between cellular proliferation and programmed cell death (apoptosis). An excess of apoptosis leads to inadequate granulation tissue formation; insufficient apoptosis can contribute to hypertrophic scarring.
LTCP has been demonstrated to promote epidermal cell proliferation (as evidenced by Ki-67 marker upregulation) while concurrently reducing pathological apoptosis (TUNEL staining analysis) across all post-operative time points assessed. This dual action — promoting life where needed, limiting unnecessary cell death — represents a biologically intelligent intervention that thermal devices cannot replicate by mechanism alone.
The OYAY LAB system's membrane potential balancing effect (as described in the SSR handpiece protocol) and the RONS-mediated modulation of key genes including Aqp5 (epidermal stem cell proliferation), Nlrp3 (inflammasome regulation), and Icam1 (inflammatory adhesion molecule) provide a mechanistic framework that aligns with this cellular homeostasis.
Section 5: Direct Comparative Safety Profile — Cold Plasma vs. Thermal Devices in Wound Healing Contexts
| Safety Parameter | OYAY LAB Cold Plasma | Non-Ablative Fractional Laser | Standard RF Device |
|---|---|---|---|
| Tissue temperature at interface | 30–50°C (physiological) | 45–65°C+ (thermal coagulation) | 40–70°C+ |
| Thermal injury to epidermis | None | Micro-coagulation zones present | Potential thermal accumulation |
| Direct anti-inflammatory effect | Yes — downregulates TNF-α, IL-6, IL-1β | No — triggers inflammatory response | No — triggers inflammatory response |
| Direct antimicrobial efficacy | Yes — disrupts bacterial membranes, resists biofilm | Minimal (surface only, 415nm) | None |
| Antibiotic resistance risk | Zero | Not applicable | Not applicable |
| Microbiome preservation | Selective — preserves beneficial bacteria | Non-selective sterilisation | Non-selective |
| Chromophore dependency | None — mechanism is non-selective by wavelength | Yes — water, melanin, Hb | Partial |
| Contraindication in inflamed skin | Low risk — anti-inflammatory | Moderate-high risk | Moderate risk |
| Growth factor upregulation | Direct — VEGF, TGF-β, bFGF, COL-I | Indirect (via thermal repair response) | Indirect |
| Suitable for aged/compromised skin | Yes — pronounced efficacy demonstrated | Caution required | Caution required |
| Recovery period required | Minimal to none | 3–7 days (NAFL) | Variable |
Section 6: Special Considerations for the Dubai Clinical Environment
Dubai's aesthetic patient demographic presents unique clinical considerations. Fitzpatrick skin types III–VI are predominant, and these skin types carry significantly higher risks of post-inflammatory hyperpigmentation (PIH) when thermal energy devices are used inappropriately, particularly in inflamed or post-procedural skin.
Cold plasma technology, by operating through a non-chromophore-dependent mechanism, carries no inherent PIH risk related to melanin absorption — a clinical advantage of considerable importance in our market. The OYAY LAB system's multi-handpiece design further allows clinicians to select the appropriate spot size and frequency for individual Fitzpatrick types without the wavelength adjustment limitations inherent to fixed-frequency laser platforms.
The SSR handpiece (35–60 Hz, 20mm spot) is particularly well-suited to broad-field wound conditioning in post-procedural recovery, while the Scan handpiece (1–50 Hz, 0.2mm spot) enables precision treatment of localised wound edges — a level of clinical versatility that no single laser platform can match.
Section 7: Clinical Applications and Recommended Integration Protocol
Based on the device specifications and the body of evidence reviewed, the OYAY LAB Cold Plasma System is clinically appropriate for the following wound-healing-related indications:
-
Post-procedural recovery (post-microneedling, post-chemical peel, post-ablative laser) — to reduce post-treatment inflammation, accelerate re-epithelialisation, and prevent secondary infection without interfering with the healing cascade.
-
Acne-associated wound healing — RONS-mediated bactericidal action against P. acnes and S. aureus combined with anti-inflammatory modulation addresses both infection and delayed healing simultaneously.
-
Chronic and subacute skin wounds — Including excoriated eczema, psoriatic plaques (noted as an indication in the OYAY LAB specification), and minor chronic ulcerations in aesthetically accessible areas.
-
Pre-surgical skin preparation — The device's antimicrobial and barrier-enhancement properties (via temporarily increased skin absorption through transient disruption of cell adhesion molecules, CAMs) support optimal pre-surgical skin conditioning.
-
Wound healing in aged or compromised skin — Research specifically demonstrates pronounced efficacy in aged subjects, where conventional healing responses are diminished.
Conclusion: A Paradigm Worthy of Professional Adoption
The aesthetic industry has, for decades, defaulted to thermal mechanisms as the primary modality for tissue regeneration. This has delivered remarkable results in skin resurfacing, tightening, and rejuvenation — and I do not suggest otherwise. Fractional laser platforms, non-ablative devices, and radiofrequency technologies each have well-established clinical roles.
However, when the clinical objective is wound healing — where the tissue is already biologically activated, where the inflammatory cascade is already in motion, and where introducing additional thermal stress risks amplifying pathological processes — cold plasma presents a mechanistically superior and evidence-supported safety profile.
OYAY LAB's Cold Plasma System delivers RONS at physiological temperatures, directly modulates the molecular drivers of inflammation and repair, eliminates pathogenic organisms without generating resistance, preserves the beneficial skin microbiome, and actively upregulates growth factor expression. It does this without thermal injury, without chromophore dependency, and without the recovery burden that thermal technologies require.
For aesthetic professionals operating at the highest level of clinical practice, understanding why a technology is safer — not merely accepting a manufacturer claim — is the professional standard. The science, in this case, is both robust and compelling.
This article is intended for licensed aesthetic and medical professionals. All device specifications referenced are sourced from OYAY LAB product documentation. Clinical efficacy claims referencing RONS mechanisms and wound healing biology are supported by peer-reviewed literature including: Zhou et al. (2025), "Low-temperature cold plasma promotes wound healing by inhibiting skin inflammation and improving skin microbiome," Frontiers in Bioengineering and Biotechnology, Vol. 13, doi: 10.3389/fbioe.2025.1511259.
Individual clinical outcomes may vary. Practitioners should conduct appropriate client assessments and adhere to local regulatory frameworks governing energy-based device use.
Tags: Cold Plasma Technology | Wound Healing | Aesthetic Medicine | OYAY LAB | Skin Regeneration | Post-Procedural Recovery | Professional Aesthetician | Clinical Technology Analysis
